Alkermes PLC (NASDAQ:ALKS) CMO Elliot Ehrich sold 11,000 shares of the company’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $56.68, for a total transaction of $623,480.00. Following the completion of the transaction, the chief marketing officer now directly owns 49,657 shares in the company, valued at approximately $2,814,558.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elliot Ehrich also recently made the following trade(s):

  • On Tuesday, January 17th, Elliot Ehrich sold 11,983 shares of Alkermes PLC stock. The stock was sold at an average price of $54.32, for a total transaction of $650,916.56.
  • On Friday, January 6th, Elliot Ehrich sold 10,000 shares of Alkermes PLC stock. The stock was sold at an average price of $59.44, for a total transaction of $594,400.00.
  • On Thursday, December 15th, Elliot Ehrich sold 5,000 shares of Alkermes PLC stock. The stock was sold at an average price of $55.99, for a total transaction of $279,950.00.
  • On Monday, December 12th, Elliot Ehrich sold 16,983 shares of Alkermes PLC stock. The stock was sold at an average price of $55.15, for a total transaction of $936,612.45.

Alkermes PLC (NASDAQ:ALKS) opened at 55.55 on Friday. The company’s market cap is $8.44 billion. Alkermes PLC has a 1-year low of $27.14 and a 1-year high of $60.74. The company has a 50-day moving average price of $55.81 and a 200-day moving average price of $52.01.

Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 15th. The company reported $0.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.11. The business had revenue of $213.50 million for the quarter, compared to analysts’ expectations of $206.38 million. Alkermes PLC had a negative net margin of 36.92% and a negative return on equity of 12.75%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.14) EPS. On average, analysts expect that Alkermes PLC will post ($0.20) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

“Alkermes PLC (ALKS) CMO Sells $623,480.00 in Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of United States & international trademark and copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/02/17/alkermes-plc-alks-cmo-sells-623480-00-in-stock.html.

Several research firms have recently weighed in on ALKS. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $51.00 price target on shares of Alkermes PLC in a report on Thursday. J P Morgan Chase & Co raised shares of Alkermes PLC from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $51.00 to $78.00 in a report on Friday, October 21st. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a report on Wednesday, November 2nd. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Tuesday, December 13th. Finally, Leerink Swann upped their price target on shares of Alkermes PLC from $57.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, October 21st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $60.75.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Massey Quick & Co. LLC acquired a new position in shares of Alkermes PLC during the fourth quarter valued at $111,000. Hall Laurie J Trustee acquired a new position in shares of Alkermes PLC during the fourth quarter valued at $154,000. Daiwa Securities Group Inc. boosted its position in shares of Alkermes PLC by 11.8% in the third quarter. Daiwa Securities Group Inc. now owns 3,800 shares of the company’s stock valued at $179,000 after buying an additional 400 shares in the last quarter. TLP Group LLC acquired a new position in shares of Alkermes PLC during the third quarter valued at $187,000. Finally, Greenwood Capital Associates LLC acquired a new position in shares of Alkermes PLC during the fourth quarter valued at $202,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

About Alkermes PLC

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

5 Day Chart for NASDAQ:ALKS

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.